4.5 Article

Gene Therapy Approaches for Lysosomal Storage Disease: Next-Generation Treatment

Journal

HUMAN GENE THERAPY
Volume 23, Issue 8, Pages 808-815

Publisher

MARY ANN LIEBERT, INC
DOI: 10.1089/hum.2012.140

Keywords

-

Funding

  1. National Institutes of Health [NHLBI P01 HL59412-06, 5F32HL095282-03]
  2. NHLBI Gene Therapy Resource Program

Ask authors/readers for more resources

Lysosomal storage diseases are a group of rare inborn errors of metabolism resulting from deficiency in normal lysosomal function. These diseases are characterized by progressive accumulation of storage material within the lysosomes of affected cells, ultimately leading to cellular dysfunction. Multiple tissues ranging from musculoskeletal and visceral to tissues of the central nervous system are typically involved in disease pathology. Since the advent of enzyme replacement therapy (ERT) to manage some LSDs, general clinical outcomes have significantly improved; however, treatment with infused protein is lifelong and continued disease progression is still evident in patients. Viral gene therapy may provide a viable alternative or adjunctive therapy to current management strategies for LSDs. In this review, we discuss the various viral vector systems that have been developed and some of the strategy designs for the treatment of LSDs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available